Pharmacy Medical News about Imatinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Imatinib: a study in the quality of adverse events reporting
Community Oncology , 10/09/09

Samaras AT et al. – This is the first study ever reported that compares the quality of clinical trial adverse event reports submitted to the FDA, IRBs, and the pharmaceutical manufacturer with the quality of information that could be developed using structured case report forms. The study found that the reports of sADEs submitted to IRBs, the FDA, and the pharmaceutical manufacturer were markedly less complete and less accurate than reports associated with the same clinical events that were derived with the assistance of structured case report forms. Increased use of structured, syndrome–specific case report forms may ultimately help improve drug safety for cancer patients.

<< Previous
Blood pressure lowering efficacy of reserpine for primary...

Next >>
Tigecycline for the treatment of patients with community-acquired...

Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09 Relevance Score: 95%

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09 Relevance Score: 91%

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09 Relevance Score: 88%

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, 10/07/09 Relevance Score: 87%

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09 Relevance Score: 87%